-
公开(公告)号：US20140227294A1
公开(公告)日：2014-08-14
申请号：US14138906
申请日：2013-12-23
Applicant: ABBVIE INC.
Inventor： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. DiGiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
Abstract translation: 本发明包括PRLR结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hPRLR具有高亲和力，并在体外和体内中和hPRLR活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hPRLR和抑制hPRLR活性，例如在患有hPRLR活性有害的病症的人类受试者中。 本发明还包括抗PRLR抗体药物偶联物（ADC）。
-
公开(公告)号：US20220289858A1
公开(公告)日：2022-09-15
申请号：US17496476
申请日：2021-10-07
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Maria A. Argiriadi , Bradford L. Mcrae , Chung-Ming Hsieh , David A. Egan , John E. Harlan , Russell A. Judge , Rui Wang , Gillian A. Kingsbury
IPC: C07K16/28 , G01N33/566
Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
-
Patent Agency Ranking
公开(公告)号：US20210074147A1
公开(公告)日：2021-03-11
申请号：US16828351
申请日：2020-03-24
Applicant: AbbVie Inc.
Inventor： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号：US10184003B2
公开(公告)日：2019-01-22
申请号：US15176137
申请日：2016-06-07
Applicant: AbbVie Inc.
Inventor： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
IPC: A61K39/395 , C07K16/00 , C07K16/28 , A61K45/06 , A61K39/00
Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号：US20210312797A9
公开(公告)日：2021-10-07
申请号：US16828351
申请日：2020-03-24
Applicant: AbbVie Inc.
Inventor： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号：US20190153110A1
公开(公告)日：2019-05-23
申请号：US16201592
申请日：2018-11-27
Applicant: AbbVie Inc.
Inventor： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
IPC: C07K16/28 , A61K39/395 , A61K45/06
Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号：US20170022281A1
公开(公告)日：2017-01-26
申请号：US15176137
申请日：2016-06-07
Applicant: AbbVie Inc.
Inventor： Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
Abstract translation: 本发明包括PRLR结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hPRLR具有高亲和力，并在体外和体内中和hPRLR活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hPRLR和抑制hPRLR活性，例如在患有hPRLR活性有害的病症的人类受试者中。 本发明还包括抗PRLR抗体药物偶联物（ADC）。
-
-
-
-
-
-
Search Results
7
records
(took 0.024 seconds)
